BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33629514)

  • 1. Expression of WW domain-containing oxidoreductase and its clinical implication in endometrial adenocarcinoma patients with metabolic syndrome.
    Shen Y; Gao L; Jiang S; Liu J; Cheng W; Shou H
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):70-75. PubMed ID: 33629514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.
    Ni J; Zhu T; Zhao L; Che F; Chen Y; Shou H; Yu A
    Clin Transl Oncol; 2015 Oct; 17(10):835-9. PubMed ID: 26260911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of ubiquitin-conjugating enzyme E2C, leucine-rich repeated-containing G protein-coupled receptor, WW domain-containing oxidoreductase, and vasculogenic mimicry in invasive breast carcinoma.
    Shen R; Wu T; Huang P; Shao Q; Chen M
    Medicine (Baltimore); 2019 Apr; 98(16):e15232. PubMed ID: 31008954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.
    Wang X; Chao L; Ma G; Chen L; Zang Y; Sun J
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):271-8. PubMed ID: 20401669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of genetic variant distributions of WW domain-containing oxidoreductase gene with uterine cervical cancer.
    Lin YH; Hsiao YH; Wu WJ; Yang SF; Hsu CF; Kang YT; Wang PH
    Int J Med Sci; 2018; 15(10):1005-1013. PubMed ID: 30013442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.
    Aldaz CM; Ferguson BW; Abba MC
    Biochim Biophys Acta; 2014 Aug; 1846(1):188-200. PubMed ID: 24932569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of WW Domain-Containing Oxidoreductase Gene Polymorphism on Clinicopathological Characteristics of Patients with EGFR Mutant Lung Adenocarcinoma in Taiwan.
    Li JP; Chang JT; Ju PC; Hsieh MH; Chao YH; Tsao TC; Hsieh MJ; Yang SF
    Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance.
    Yu L; Mao X; Wu S; Zhou L; Song W; Gong X; Wang D
    Int J Clin Exp Pathol; 2019; 12(1):327-336. PubMed ID: 31933749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 (BMI-1) and WW Domain-Containing Oxidoreductase (WWOX) in Liver Cancer Tissue and Normal Liver Tissue.
    Yu J; Hu M; Chen W; Wen Z
    Med Sci Monit; 2018 Sep; 24():6673-6679. PubMed ID: 30242144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
    Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
    Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations.
    Maeda N; Semba S; Nakayama S; Yanagihara K; Yokozaki H
    Virchows Arch; 2010 Oct; 457(4):423-32. PubMed ID: 20737170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study.
    Lan C; Chenggang W; Yulan B; Xiaohui D; Junhui Z; Xiao W
    Int J Gynecol Pathol; 2012 Mar; 31(2):125-32. PubMed ID: 22317867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.
    Kurek KC; Del Mare S; Salah Z; Abdeen S; Sadiq H; Lee SH; Gaudio E; Zanesi N; Jones KB; DeYoung B; Amir G; Gebhardt M; Warman M; Stein GS; Stein JL; Lian JB; Aqeilan RI
    Cancer Res; 2010 Jul; 70(13):5577-86. PubMed ID: 20530675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical WWOX Expression and Association with Angiogenesis, p53 Expression, Cell Proliferation and Clinicopathological Parameters in Cervical Cancer.
    Seabra MAL; Cândido EB; Vidigal PVT; Lamaita RM; Rodrigues AN; Silva Filho ALD
    Rev Bras Ginecol Obstet; 2018 Feb; 40(2):79-85. PubMed ID: 29310145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.
    Abu-Odeh M; Bar-Mag T; Huang H; Kim T; Salah Z; Abdeen SK; Sudol M; Reichmann D; Sidhu S; Kim PM; Aqeilan RI
    J Biol Chem; 2014 Mar; 289(13):8865-80. PubMed ID: 24550385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ORAOV1, CD133 and WWOX correlate with metastasis and prognosis in gastric adenocarcinoma.
    Lu G; Zhou L; Song W; Wu S; Zhu B; Wang D
    Int J Clin Exp Pathol; 2017; 10(8):8916-8924. PubMed ID: 31966760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
    Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
    Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of fragile histidine triad (FHIT) and WW-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma.
    Chen X; Li P; Yang Z; Mo WN
    Asian Pac J Cancer Prev; 2013; 14(1):165-71. PubMed ID: 23534718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.
    Zhou C; Chen W; Sun J; Atyah M; Yin Y; Zhang W; Guo L; Ye Q; Dong Q; Shi Y; Ren N
    Cancer Med; 2018 Jul; 7(7):3031-3043. PubMed ID: 29905011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.